Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Descartes-11

Cell therapy (CAR-T) · developed by Cartesian Therapeutics

Phase 2 Most advanced trial (none active)
RNAC Developer
2 Registered trials

What is Descartes-11?

Descartes-11 is a CAR-T cell therapy directed against BCMA for the treatment of multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Descartes 11
Drug type
Cell therapy (CAR-T)
Therapy area
Oncology
Developer
Cartesian Therapeutics (RNAC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04436029 Phase 2 Multiple Myeloma Completed RNAC
NCT03994705 Phase 1 Multiple Myeloma Terminated RNAC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

More from Cartesian Therapeutics

Descartes 30 Phase 1 Descartes-08 Phase 3 Descartes-15 Phase 1 Descartes-25 Phase 1

Follow RNAC, the company behind Descartes-11

See RNAC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RNAC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.